Two studies confirm positive benefit-risk profile of XARELTO in treating VTE

Janssen Pharmaceuticals and its development partner Bayer announced results of two new real-world studies, which confirmed the positive benefit-risk profile of XARELTO (rivaroxaban) in treating venous thromboembolism (VTE), or blood clots, and minimi …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals